Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I/II Dose Escalation Study Evaluating Safety and Activity of Autologous CD34+-Enriched Hematopoietic Progenitor Cells Genetically Modified With a Lentiviral Vector Encoding for the Human Interferon-ɑ2 Gene in Multiple Myeloma Patients With Early Relapse After Intensive Front Line Therapy

Next Previous
Trial Profile

A Phase I/II Dose Escalation Study Evaluating Safety and Activity of Autologous CD34+-Enriched Hematopoietic Progenitor Cells Genetically Modified With a Lentiviral Vector Encoding for the Human Interferon-ɑ2 Gene in Multiple Myeloma Patients With Early Relapse After Intensive Front Line Therapy

Status: Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 02 Jan 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Interferon alpha 2 gen e therapy-GenentaScience (Primary) ; Bortezomib; Cyclophosphamide; Dexamethasone; Filgrastim; Lenalidomide; Lenograstim; Melphalan; Plerixafor
  • Indications Multiple myeloma
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Acronyms TEM-MM
  • Sponsors Genenta Science

Most Recent Events

  • 27 Jan 2022 Status changed from recruiting to discontinued, reason: failure to recruit patients
  • 10 Dec 2019 Trial design assessing Safety and Activity of Human Interferon-a2 in Multiple Myeloma Patients with Early Relapse after Intensive Front Line Therapy Results presented at the 61st Annual Meeting and Exposition of the American Society of Hematology
  • 13 Mar 2019 Status changed from planning to recruiting.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top